[1]
Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65, 1631-1652.
[2]
Corson, T.W.; Crews, C.M. Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell, 2007, 130, 769-774.
[3]
Bar-Sela, G.; Epelbaum, R.; Schaffer, M. Curcumin as an anti-cancer agent: Review of the gap between basic and clinical applications. Curr. Med. Chem., 2010, 17, 190-197.
[4]
Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev., 2009, 14, 141-153.
[5]
Hamaguchi, T.; Ono, K.; Yamada, M. Curcumin and Alzheimer’s disease. CNS Neurosci. Ther., 2010, 16, 285-297.
[6]
Ahmad, B.; Borana, M.S.; Chaudhary, A.P. Understanding curcumin-induced modulation of protein aggregation. Int. J. Biol. Macromol., 2017, 100, 89-96.
[7]
Oda, Y. Inhibitory effect of curcumin on SOS functions induced by UV irradiation. Mutat. Res. Lett., 1995, 348, 67-73.
[8]
Reddy, A.R.; Dinesh, P.; Prabhakar, A.S.; Umasankar, K.; Shireesha, B.; Raju, M.B. A comprehensive review on SAR of curcumin. Mini Rev. Med. Chem., 2013, 13, 1769-1777.
[9]
Cridge, B.J.; Larsen, L.; Rosengren, R.J. Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncol. Discov., 2013, 1(1), 6.
[10]
Pillai, G.R.; Srivastava, A.S.; Hassanein, T.I.; Chauhan, D.P.; Carrier, E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett., 2004, 208, 163-170.
[11]
Wan, S.B.; Yang, H.; Zhou, Z.; Cui, Q.C.; Chen, D.; Kanwar, J.; Mohammad, I.; Dou, Q.P.; Chan, T.H. Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. Int. J. Mol. Med., 2010, 26, 447-455.
[12]
Bush, J.A.; Cheung, K-J.J.; Li, G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res., 2001, 271, 305-314.
[13]
Wilken, R.; Veena, M.S.; Wang, M.B.; Srivatsan, E.S. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer, 2011, 10, 12.
[14]
Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm., 2007, 4, 807-818.
[15]
Zhang, Q.; Zhong, Y.; Yan, L.N.; Sun, X.; Gong, T.; Zhang, Z.R. Synthesis and preliminary evaluation of curcumin analogues as cytotoxic agents. Bioorg. Med. Chem. Lett., 2011, 21, 1010-1014.
[16]
Liang, G.; Shao, L.; Wang, Y.; Zhao, C.; Chu, Y.; Xiao, J.; Zhao, Y.; Li, X.; Yang, S. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem., 2009, 17, 2623-2631.
[17]
Vyas, A.; Dandawate, P.; Padhye, S.; Ahmad, A.; Sarkar, F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr. Pharm. Des., 2013, 19, 2047-2069.
[18]
Lin, L.; Shi, Q.; Nyarko, A.K.; Bastow, K.F.; Wu, C.C.; Su, C.Y.; Shih, C.C.Y.; Lee, K.H. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J. Med. Chem., 2006, 49, 3963-3972.
[19]
Yamakoshi, H.; Ohori, H.; Kudo, C.; Sato, A.; Kanoh, N.; Ishioka, C.; Shibata, H.; Iwabuchi, Y. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg. Med. Chem., 2010, 18, 1083-1092.
[20]
Ohori, H.; Yamakoshi, H.; Tomizawa, M.; Shibuya, M.; Kakudo, Y.; Takahashi, A.; Takahashi, S.; Kato, S.; Suzuki, T.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Synthesis and biolgical analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., 2006, 5(10), 2563-2571.
[21]
Ferrari, E.; Pignedoli, F.; Imbriano, C.; Marverti, G.; Basile, V.; Venturi, E.; Saladini, M. Newly synthesized curcumin derivatives: crosstalk between chemico-physical properties and biological activity. J. Med. Chem., 2011, 54, 8066-8077.
[22]
Lin, L.; Shi, Q.; Su, C.Y.; Shih, C.C.Y.; Lee, K.H. Antitumor agents 247. New 4-ethoxycarbonyl ethylcurcumin analogs as potential antiandrogenic agents. Bioorg. Med. Chem., 2006, 14, 2527-2534.
[23]
Bayomi, S.M.; El-Kashef, H.A.; El-Ashmawy, M.B.; Nasr, M.N.A.; El-Sherbeny, M.A.; Badria, F.A.; Abou-Zeid, L.A.; Ghaly, M.A.; Abdel-Aziz, N.I. Synthesis and biological evaluation of new curcumin derivatives as antioxidant and antitumor agents. Med. Chem. Res., 2013, 22, 1147-1162.
[24]
Shao, W.Y.; Cao, Y.N.; Yu, Z.W.; Pan, W.J.; Qiu, X.; Bu, X.Z.; An, L.K.; Huang, Z.S.; Gu, L.Q.; Chan, A.S.C. Facile preparation of new unsymmetrical curcumin derivatives by solid-phase synthesis strategy. Tetrahedron Lett., 2006, 47, 4085-4089.
[25]
Shi, W.; Dolai, S.; Rizk, S.; Hussain, A.; Tariq, H.; Averick, S.; L’Amoreaux, W.; El-Idrissi, A.; Banerjee, P.; Raja, K. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org. Lett., 2007, 9, 5461-5464.
[26]
Tang, H.; Murphy, C.J.; Zhang, B.; Shen, Y.; Van Kirk, E.A.; Murdoch, W.J.; Radosz, M. Curcumin polymers as anticancer conjugates. Biomaterials, 2010, 31, 7139-7149.
[27]
Safavy, A.; Raisch, K.P.; Mantena, S.; Sanford, L.L.; Sham, S.W.; Krishna, N.R.; Bonner, J.A. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J. Med. Chem., 2007, 50, 6284-6288.
[28]
Yen, F.L.; Wu, T.H.; Tzeng, C.W.; Lin, L.T.; Lin, C.C. Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities. J. Agric. Food Chem., 2010, 58, 7376-7382.
[29]
Aggarwal, S.; Ndinguri, M.W.; Solipuram, R.; Wakamatsu, N.; Hammer, R.P.; Ingram, D.; Hansel, W. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int. J. Cancer, 2011, 129, 1611-1623.
[30]
Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discov. Today, 2012, 17, 71-80.
[31]
Teiten, M.H.; Dicato, M.; Diederich, M. Hybrid curcumin compounds: A new strategy for cancer treatment. Molecules, 2014, 19, 20839-20863.
[32]
Liu, K.; Guo, T.L.; Chojnacki, J.; Lee, H.G.; Wang, X.; Siedlak, S.L.; Rao, W.; Zhu, X.; Zhang, S. Bivalent ligand containing curcumin and cholesterol as fluorescence probe for Aβ plaques in Alzheimer’s disease. ACS Chem. Neurosci., 2012, 3, 141-146.
[33]
Singh, R.K.; Rai, D.; Yadav, D.; Bhargava, A.; Balzarini, J.; De Clercq, E. Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid. Eur. J. Med. Chem., 2010, 45, 1078-1086.
[34]
Freeman, C.L.; Swords, R.; Giles, F.J. Amonafide: A future in treatment of resistant and secondary acute myeloid leukemia? Expert Rev. Hematol., 2012, 5, 17-26.
[35]
Knauf, W.U.; Lissitchkov, T.; Aldaoud, A.; Liberati, A.M.; Loscertales, J.; Herbrecht, R.; Juliusson, G.; Postner, G.; Gercheva, L.; Goranov, S.; Becker, M.; Fricke, H.J.; Huguet, F.; Del Giudice, I.; Klein, P.; Merkle, K.; Montillo, M. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: Updated results of a randomized phase III trial. Br. J. Haematol., 2012, 159, 67-77.
[36]
Wada, K.; Lee, J.Y.; Hung, H.Y.; Shi, Q.; Lin, L.; Zhao, Y.; Goto, M.; Yang, P.C.; Kuo, S.C.; Chen, H.W.; Lee, K.H. Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects. Bioorg. Med. Chem., 2015, 23, 1507-1514.
[37]
Bi, W.; Bi, Y.; Gao, X.; Yan, X.; Zhang, Y.; Harris, J.; Legalley, T.D.; Gibson, K.M.; Bi, L. Pharmacological protection of mitochondrial function mitigates acute limb ischemia/reperfusion injury. Bioorg. Med. Chem. Lett., 2016, 26, 4042-4051.
[38]
Sribalan, R.; Kirubavathi, M.; Banuppriya, G.; Padmini, V. Synthesis and biological evaluation of new symmetric curcumin derivatives. Bioorg. Med. Chem. Lett., 2015, 25, 4282-4286.
[39]
Arezki, A.; Brule, E.; Jaouen, G. Synthesis and structure-activity relationships of the first Ferrocenyl-Aryl-Hydantoin derivatives of the nonsteroidal Antiandrogen Nilutamide. Organometallics, 2009, 28, 1606-1609.
[40]
Changtam, C.; Hongmanee, P.; Suksamrarn, A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur. J. Med. Chem., 2010, 45, 4446-4457.
[41]
Ragozin, E.; Redko, B.; Tuchinsky, E.; Rozovsky, A.; Albeck, A.; Grynszpan, F.; Gellerman, G. Biolabile peptidyl delivery systems toward sequential drug release. Biopolymers Pep. Sci., 2015, 106, 119-132.
[42]
Chen, C.; Wang, Z.; Zhang, Z.; Liu, X. Kang; Zhang, Y.; Ye, K. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 2018, 115(3), 578-583.
[43]
Zhang, X.; Lin, Y.; Gillies, R.J. Tumor pH and its measurement. J. Nucl. Med., 2010, 51(8), 1167-1170.
[44]
Bazylevich, A.; Patsenker, L.D.; Gellerman, G. Exploiting fluorescein based drug conjugates for fluorescentmonitoring in drug delivery. Dyes Pigments, 2017, 139, 460-472.
[45]
Gilad, Y.; Firer, M.A.; Rozovsky, A.; Ragozin, E.; Redko, B.; Albeck, A.; Gellerman, G. “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide.. Eur. J. Med. Chem., 2014, 85, 139-146.
[46]
Fujisawa, S.; Atsumi, T.; Ishihara, M.; Kadoma, Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res., 2004, 24, 563-569.
[47]
Sökmen, M.; Akram, K.M. The antioxidant activity of some curcuminoids and chalcones. Inflammopharmacology, 2016, 24, 81-86.
[48]
Bothon, F.T.D.; Debiton, E.; Avlessi, F.; Forestier, C.; Teulade, J-C.; Sohounhloue, D.K.C. in vitro biological effects of two anti-diabetic medicinal plants used in Benin as folk medicine. BMC Complement. Altern. Med., 2013, 13, 51.
[49]
Wang, W.; Abbruzzese, J.L.; Evans, D.B.; Larry, L.; Cleary, K.R.; Chiao, P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 1999, 5, 119-127.
[50]
Bours, V.; Dejardin, E.; Goujon-Letawe, F.; Merville, M.P.; Castronovo, V. The NF-kappa B transcription factor and cancer: High expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem. Pharmacol., 1994, 47, 145-149.
[51]
Sovak, M.A.; Bellas, R.E.; Kim, D.W.; Zanieski, G.J.; Rogers, A.E.; Traish, A.M.; Sonenshein, G.E. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest., 1997, 100, 2952-2960.
[52]
Yang, J.; Richmond, A. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res., 2001, 61, 4901-4909.
[53]
Devalaraja, M.N.; Wang, D.Z.; Ballard, D.W.; Richmond, A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res., 1999, 59, 1372-1377.
[54]
Liao, W.; Xiang, W.; Wang, F.F.; Wang, R.; Ding, Y. Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress. Biomed. Pharmacother., 2017, 95, 1177-1186.
[55]
Liao, W.; Xiang, W.; Wang, F.F.; Wang, R.; Ding, Y. Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress. Biomed. Pharmacother., 2017, 95, 1177-1186.
[56]
Zhao, G.; Han, X.; Zheng, S.; Li, Z.; Sha, Y.; Ni, J.; Sun, Z.; Qiao, S.; Song, Z. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells. Oncol. Rep., 2016, 35, 1065-1074.
[57]
Mirzaei, H.; Naseri, G.; Rezaee, R.; Mohammadi, M.; Banikazemi, Z.; Mirzaei, H.R.; Salehi, H.; Peyvandi, M.; Pawelek, J.M.; Sahebkar, A. Curcumin: A new candidate for melanoma therapy? Int. J. Cancer, 2016, 139, 1683-1695.
[58]
Chen, L.; Williams, S.A.; Mu, Y.; Nakano, H.; Duerr, J.M.; Buckbinder, L.; Greene, W.C. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol., 2005, 25, 7966-7975.
35
3